WO1999008658A1 - Fast-dissolving comestible units formed under high-speed/high-pressure conditions - Google Patents
Fast-dissolving comestible units formed under high-speed/high-pressure conditions Download PDFInfo
- Publication number
- WO1999008658A1 WO1999008658A1 PCT/US1998/016520 US9816520W WO9908658A1 WO 1999008658 A1 WO1999008658 A1 WO 1999008658A1 US 9816520 W US9816520 W US 9816520W WO 9908658 A1 WO9908658 A1 WO 9908658A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- floss
- agents
- composition
- hydrochloride
- matrix
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
Definitions
- the invention deals with compositions having enhanced cohesive and self-binding properties which permit tableting without added glycerine. Tablets made herewith disintegrate rapidly when placed in the mouth, especially when chewed.
- shearform matrices for forming comestible units is described in WO95/34290 (published December 21, 1995) from co-assigned PCT application No. PCT/US95/07144, filed June 6, 1995.
- This case discloses a quick dissolving tablet which is formed by: (1) using flash-flow technology to provide a shearform matrix; (2) combining the partially recrystallized shearform matrix with an additive to form flowable, compactible particulate blends; and (3) compacting the blends at relatively low pressures to form comestible units, such as tablets.
- PCT publication WO 95/34293 (published December 21, 1995) from co-assigned PCT Application No. PCT/US95/07194, filed June 6, 1995, discloses a process and apparatus for making rapidly dissolving dosage units by flash-flow processing.
- a shearform matrix is formed by the flash-flow process, the shearform matrix is combined with an additive, and the matrix is molded to make a unit dosage form. Tamping may be used to compact the dosage form and increase its integrity.
- tablet compositions derived from hygroscopic matrices containing these sugar alcohols are useful— in the presence of tableting aids and crystallization promoters— in both high- and low-pressure tableting processes. Tablets therefrom rapidly dissolve when placed in the mouth, generally in less than 30 seconds, especially when chewed.
- the tablet compositions of the invention are based on matrices which comprise at least one sugar alcohol, which matrices fall into one of the following groups:
- matrices which comprise at least one sugar alcohol, which matrices fall into one of the following groups:
- a second group termed “dual floss”— is exemplified by (I) a first shearform carrier matrix (the “base floss”) comprising a carrier and at least one sugar alcohol, generally sorbitol; and (II) a second shearform binder matrix (the “binder floss”) comprising a carrier and xylitol.
- base floss a first shearform carrier matrix
- binder floss a second shearform binder matrix
- Actives and other conventional tablet ingredients can be added, in suitable amounts, to the compositions of the present invention during the production of the matrices and/or after the matrices are collected and chopped, but before tableting.
- matrix and “floss” are used interchangeably. Applicants have found that by using a combination of certain ingredients and process steps, tablets that dissolve in the mouth, with optional chewing, can be produced using conventional tableting equipment.
- the dissolution time, in the mouth, for tablets made from this composition is in the range of from about 3 seconds to about 30 seconds.
- Prior art compositions required the use of specialized, low-pressure (less than 1000 psi) tableting equipment.
- the preparation of flosses suitable for use in the present invention is disclosed in co-assigned patent publications WO 95/34290 and WO 95/34293, both incorporated herein by reference.
- the floss is a "shearform matrix" produced by subjecting a feedstock which contains a sugar carrier to flash-heat processing.
- the feedstock is simultaneously subjected to centrifugal force and to a temperature gradient which raises the temperature of the mass to create an internal flow condition which permits part of it to move with respect to the rest of the mass.
- the flowing mass exits through openings provided in the perimeter of a spinning head.
- the temperature gradient is supplied using heaters or other means which cause the mass temperature to rise. Centrifugal force in the spinning head flings the internally flowing mass outwardly, so that it reforms as discrete fibers with changed structures.
- One apparatus which produces suitable conditions is a modified floss making machine, such as that described in
- Spinning is typically conducted at temperatures and speeds of about 150° C to 250°C and 3,000 to 5,000 rpm, respectively.
- Suitable spinner heads include that disclosed in U. S. Patent 5,458,823, assigned to Applicants' assignee. Other apparatuses and processes which provide similar forces and temperature gradient conditions can be used.
- the matrices used herein include, as feedstock ingredients, carrier materials, which carriers comprise at least one ingredient selected from materials which are capable of undergoing the physical and/or chemical changes associated with flash heat processing.
- Useful carriers include carbohydrates which become free-form particulates when flash heat processed. Saccharide-based carriers, including saccharides (i.e., sugars), polysaccharides and mixtures thereof can be also used.
- the feedstocks used in the invention can include carriers chosen from various classes of "sugars.”
- “Sugars” are those substances which are based on simple crystalline mono- and di-saccharide structures, i.e., based on C 5 and C 6 sugar structures. They may include glucose, sucrose, fructose, lactose, maltose, pentose, arbinose, xylose, ribose, mannose, galactose, sorbose, dextrose and sugar alcohols, such as sorbitol, mannitol, xylitol, maltitol, isomalt, sucralose and the like and mixtures thereof.
- Sucrose is the preferred sugar.
- Useful mixtures of carriers include the sugars listed above along with additional mono- di-, tri- and polysaccharides. Additional saccharides can be used in amounts of up to 50% by weight, preferably up to 30%, most preferably up to 20%, of the total carbohydrate content.
- polysaccharides can be used alone as carriers.
- Polysaccharide carriers include polydextrose and the like.
- Polydextrose is a non-sucrose, essentially non- nutritive, carbohydrate substitute. It can be prepared through polymerization of glucose in the presence of polycarboxylic acid catalysts and polyols.
- polydextrose is commercially available in three forms: polydextrose A and polydextrose K, which are powdered solids; and polydextrose N supplied as a 70% solution.
- U.S. Patent No. 5,501,858 discusses polydextrose carriers.
- maltodextrins include mixtures of carbohydrates resulting from the hydrolysis of a saccharide. They are solids having a dextrose equivalent (DE) of up to and including 65.
- DE dextrose equivalent
- the carrier can also include maltooligo-saccharides produced by selective hydrolysis of corn starch. A general description of maltooligo-saccharides useful herein is set forth in co-owned U.S. Patent Nos. 5,347,431 and 5,429,836.
- Applicants typically use the following systems of matrices, which systems are devoid of glycerine.
- xylitol is added to a mixture of saccharide-based carrier and one or more additional sugar alcohols, with sorbitol being favored as an added sugar alcohol.
- the carrier mix is flash-heat processed to provide a shearform floss having self- binding properties.
- Flosses made using sucrose, sorbitol and xylitol have been found to yield particularly effective self-binding properties. They exemplify "single floss” or "unifloss" systems.
- the second system makes separate xylitol-containing binder flosses.
- the binder flosses ( binder portions ) are combined with base flosses ( base portions ), which contain a different sugar alcohol and a saccharide.
- the base floss contains sorbitol and sucrose, while the binder floss contains xylitol and possibly sorbitol. These are termed "dual floss" systems.
- the ingredients which increase cohesiveness and lend self-binding properties preferably include sugar alcohols, such as sorbitol, xylitol, maltitol, mannitol and mixtures thereof, all of which form flosses. It is believed that the hygroscopic nature of these sugar alcohols increases the cohesiveness and self-binding character of matrices and matrix-containing formulations. Other sugar alcohols, especially hygroscopic ones, are contemplated.
- Xylitol and sorbitol are the preferred sugar alcohols. Effective amounts of xylitol in the flosses are between about 0.5% and 25%, and preferably about 10% by weight. Sorbitol is used in the flosses in amounts of about 0.5% to about 40%. When sorbitol and xylitol are used, the ratio of sorbitol to xylitol is from about
- xylitol-containing, or binder, floss In dual floss systems, about 20 to about 80%, preferably about 34%, of the total floss content is xylitol-containing, or binder, floss. Likewise, the sorbitol-containing, or base, floss may be about 20 to 80 % of the total floss. In some "dual floss" embodiments, xylitol-containing flosses are first mixed with active ingredient(s), then mixed with sucrose/sorbitol flosses.
- the total floss content preferably includes about 50 to about 85% sucrose, about 5 to about 20% sorbitol and about 5% to about 25% xylitol.
- flosses are used along with bio-affecting, or active, agents in the form of microsphere granulates or crystalline particles in the tableting process. It is preferred that the bio-affecting agent be coated as well.
- a xylitol-containing floss is added to microspheres of one or more active agents first and then a non-xylitol- containing floss is added.
- the weight ratio of total floss to microspheres is about 1:1. In these instances, about 5% to about 25% of the floss is xylitol.
- the amorphous shearform matrix of the present invention is preferably made from a feedstock which includes sucrose, sorbitol, and xylitol. As set forth in U.S.S.N. 08/915,068, filed August 20, 1997, these compositions have superior cohesiveness.
- the matrices when partially recrystallized, yield matrix-containing mixes having particulate flowability such that they are suitable for use in high-speed and high-pressure tableting equipment to yield fast-dissolving tablets.
- Applicants do not wish to be bound by a particular theory; however, they believe that a hygroscopic material must be present in the matrices and the matrices must be at least partially crystallized to provide good cohesiveness, self-binding properties and flow characteristics to the compositions containing them.
- the hygroscopic material is initially present in the matrix in its amorphous state, but, due to its propensity to pick up moisture, it recrystallizes into a more crystalline structure.
- the composition can be tableted on conventional tableting machines.
- compositions to be processed into comestible, or dosage, units generally contain conventional tableting additives.
- Conventional quantities of same may be incorporated into one or more of the matrices or may be mixed therewith prior to tableting.
- Useful amounts of conventional additives range from about 0.01% to about 80% by weight, based on the weight of the matrices or formulations in which they are used. The quantities may vary from these amounts, depending on the functions of the additives and the characteristics desired in the matrices and/or the final tablet compositions.
- Conventional tableting aids and additives may be selected from a wide variety of materials such as lubricants, glidants, anti-caking agents and flow agents.
- lubricants such as magnesium stearate, calcium stearate, sodium chloride, zinc stearate, hydrogenated vegetable oils, sterotex, polyoxyethylene, glyceryl monostearate, talc, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, magnesium lauryl sulfate, sodium stearyl fumarate, adipic acid, light mineral oil and the like may be employed, with sodium stearyl fumarate preferred.
- Waxy fatty acid esters such as glyceryl behenate, sold as "Compritol" products, can be used. Mixtures are operable.
- Lubricants are used in amounts ranging from about 0% to about 10%, with about 0.01% to about 5.0% typically used.
- Glidants such as starch, talc, lactose, stearates, dibasic calcium phosphate, magnesium carbonate, magnesium oxide, calcium silicate, CabosilTM SyloidTM and silicon dioxide aerogels may be employed.
- Lactose which may be a glidant or filler, can be added to the chopped floss at about 2% concentration to inhibit clumping.
- the floss is chopped in the presence of lactose.
- Glidants are present in amounts of about 0% to about 20%, with typical amounts being about 0.1% to about 5.0%.
- the preformed matrices produced in accordance herewith are generally rendered partially crystalline, either alone or in the presence of additives, by one or more of the following crystallizing techniques.
- the nature of the matrix feedstock determines whether the matrix is to be crystallized or recrystallized after it is formed. Highly amorphous feedstocks are crystallized. Crystalline ones are recrystallized. Nonetheless, the terms "crystallization” and “recrystallization” are used interchangeably in the following discussion.
- the amorphous matrices are typically recrystallized by incorporating into, or contacting them with one or more crystallization promoters, termed “crystallization enhancers' and “crystallization modifiers.” Both types of promoters assist in the recrystallization.
- crystallization enhancers are generally forces or physical materials that are used after the floss has been formed, but before the floss-containing composition is tableted.
- Suitable crystallization enhancers include ethanol, polyvinylpyrrolidone, water (e.g., moisture), glycerine, radiant energy (e.g., microwaves, heat, etc.) and the like. Combinations can be used.
- recrystallization involves physical materials, as enhancers, typical amounts of these enhancers range from about 0.01% to about 10.0% by weight of the tablet composition.
- Another crystallization technique involves crystallization modifiers.
- crystallization modifiers are either (a) floss ingredients used at levels of about 0.01% to about 20.0% by weight of the floss, or (b) a combination of ingredients (a) with environmental agents or forces such as increased moisture and heat.
- the combination of additives with heat/humidity is called "aging.”
- Surfactants are preferred crystallization modifiers.
- Other materials which are non- saccharide hydrophilic organic materials may also be used.
- Useful modifiers preferably have a hydrophilic to lipid balance (HLB) of about 6 or more. Such materials include, without limitation, anionic, cationic, and zwitterionic surfactants as well as neutral materials with suitable HLB values.
- Hydrophilic materials having polyethylene oxide linkages are effective. Those with molecular weights of at least about 200, preferably at least 400, are highly useful.
- Crystallization modifiers useful herein include: lecithin, polyethylene glycol (PEG), propylene glycol (PPG), dextrose, the SPANS and TWEENS which are commercially available from ICI America, and the surface active agents known as Carbowaxes . Generally, the polyoxyethylene sorbitan fatty acid esters called TWEENS, or combinations of such modifiers are used. Crystallization modifiers are usually incorporated into matrices in amounts of between about 0% and 10%.
- crystallization modifiers and/or enhancers are used at levels sufficient to give the floss/additive mixes the cohesivity and particular flowability needed for further processing, e.g. , molding into tablets.
- the matrices are allowed to recrystallize, with or without added crystallization assistants, i.e., modifiers and enhancers, either before or after they are combined with the non-matrix component(s), e.g., the bio-affecting additives(s).
- the recrystallization level of the matrix generally reaches at least about 10% before tableting. Crystallization levels of 20% or more are highly effective.
- the use of partially recrystallized matrices leads to compositions that are free flowing and tabletable using conventional machines.
- U. S. Patent 5,597,416 describes a process for recrystallizing in the presence of additives.
- Methods for effecting the recrystallization of the matrices include one or more of the following: use of Tween 80 or other crystallization modifier(s) in the matrix premix; aging of the matrix for up to several weeks; contacting the matrix with sufficient moisture and heat to induce crystallization; and treating the floss or the floss-containing composition with ethanol, ethanol vapors or another crystallization enhancer. Combinations of these may be used so that the matrices may be contacted with a crystallization enhancer while they are also in contact with moisture or heat.
- a surfactant such as a Tween
- about 0.001% to about 1.00% is included in the floss preblend as a crystallization modifier.
- the formulations are processed into flosses, then chopped and used, with or without additives, to make tablets. Mixtures of surfactants can be used.
- Aging may be used to recrystallize the matrix or floss.
- the aging process involves two steps. First the matrix, optionally containing at least one crystallization modifier, is formed, chopped and allowed to stand in closed or sealed containers without agitation under ambient conditions, e.g., at room temperature and atmospheric pressure, for up to several days, preferably for about 1 to about 3 days. Later, the matrix is mixed, and optionally further chopped, with one or more other ingredients. The mix is then aged by allowing it to stand for an additional period of about 1 to about 3 days. Generally, the two-step aging process takes a total of about one week, with periods of about 4 to about 5 days being typical.
- the flosses may also be recrystallized by subjecting them to increased heat and moisture without additives. This process is similar to aging, but involves shorter periods of time.
- chopped floss is fluidized while heating, at ambient humidity and pressure, to a temperature of about 25°C to about 50°C. Generally, the temperature must be monitored to minimize clumping of floss particles. If any clumping occurs, the floss particles must be sieved before being further processed. Heating times of about 5 to about 30 minutes are typical.
- ethanol When ethanol is used as a crystallization enhancer it is used in amounts, based upon the weight of the matrix, of about 0.1% to about 10%, with amounts of about 0.5% to about 8.0%, about 0.5% to about 7.0%, being very effective.
- the preformed matrix is contacted with ethanol. Excess ethanol is evaporated by drying for about 60 to 150 minutes at about 95°F to about 115°F, with 95°F to 105°F being highly useful. The drying step is carried out using tray drying, a jacketed mixer or other suitable method. Ethanol vapors may also be used. Following ethanol treatment, the matrix becomes partially. When the floss is partially recrystallized, it is granulated and tableted after blending with other ingredients. The tableting compositions flow readily and are cohesive.
- partially crystalline ethanol- treated flosses be used. These flosses, often on optional lactose treatment (i.e., chopping in the presence of lactose) are used in tabletable compositions.
- Recrystallization of the matrix can be monitored by measuring the transmittance of polarized light therethrough or by the use of a scanning electron microscope.
- Amorphous floss or shearform matrix does not transmit polarized light and appears black in the light microscope when viewed with polarized light. Using bright field microscopy or the scanning electron microscope, the surface of the floss appears very smooth. In this condition, it is 0% recrystallized. That is, the floss is 100% amorphous. Recrystallization of amorphous matrix starts at the surface of the mass and can be modified, e.g., accelerated, by the presence of crystallization modifiers, as well as moisture. When Tweens assist the recrystallization, initiation of recrystallization is evidenced by a birefringence observed on the surface of the shearform matrix (floss) as viewed with polarized light. There are faint points of light riddled throughout the matrix surface. When birefringence appears, recrystallization has begun. At this stage, recrystallization is between about 1% and 5%.
- the recrystallization of the matrix results in reduction of the total volume of material. Ordered arrays of molecules take up less space than disordered arrays. Since recrystallization begins at the surface of the floss, a crust is formed which maintains the size and shape of the floss. There is an increase in the total free volume space within the floss as recrystallization nears completion, which manifests itself as a void inside the floss. This is evidenced by a darkened central cavity in light microscopy and a hollow interior in scanning electron microscopy. At this stage, the floss is believed to be about 50% to about 75% recrystallized.
- the intensity of transmitted polarized light increases as the floss becomes more crystalline. The polarized light can be measured by a photon detector and assigned a value against calculated standards on a gray-scale.
- the final observable event in the recrystallization of floss is the appearance of fine, "cat whisker-like" needles and tiny blades which grow and project from the surface of the floss. These fine crystals, believed to be sorbitol (cat whiskers) and xylitol (blades), literally cover the floss like a blanket of fuzz. These features can be easily recognized by both light and electron microscopes. Their appearance indicates the final stage of recrystallization.
- the floss is now 100% recrystallized, i.e., substantially non- amorphous.
- the matrix portions of the tabletable composition are typically formed via flash- heat processing into a floss.
- the strands of the floss are macerated or chopped into rods for further processing.
- the rods of chopped floss have lengths of about 50 to about 500 microns.
- Suitable microspheres and other spheroidal particles can be made by "liquiflash” processes.
- “Liquiflash” processing involves the use of heat and pressure to reduce the feedstock to a condition in which resistance to flow, e.g., viscosity, which impedes the propensity to form liquid droplets, is eliminated. In this condition, the mass has become liquid or liqiuform.” Once all resistance to flow is gone, shear force is applied to the feedstock until discrete particles separate from the mass.
- the particles called “shearlite” particles, have a size and shape influenced only by natural mass separation of the flowing feedstock.
- inventive compositions may include one or more active ingredients, such as bio-affecting agents. These are typically prescription or over the counter medications.
- active ingredients useful herein can be selected from a large group of therapeutic agents.
- Respective classes include those in the following therapeutic categories: ace-inhibitors; alkaloids; antacids; analgesics; anabolic agents; anti-anginal drugs; anti-allergy agents; anti-arrhythmia agents; antiasthmatics; antibiotics; anticholesterolemics; anticonvulsants; anticoagulants; antidepressants; antidiarrheal preparations; anti-emetics; antihistamines; antihypertensives; anti-infectives; anti- inflammatories; antilipid agents; antimanics; anti-migraine agents; antinauseants; antipsychotics; antistroke agents; antithyroid preparations; anabolic drugs; antiobesity agents; antiparasitics; antipsychotics; antipyretics; antispasmodics; antithrombotics; antitumor agents; antitussives; antiulcer agents; anti-uricemic agents; anxiolytic agents; appetite stimulants; appetite suppressants; beta-block
- Active agents which may be used in the invention include: acetaminophen; acetic acid; acetylsalicylic acid, including its buffered forms; acrivastine; albuterol and its sulfate; alcohol; alkaline phosphatase; allantoin; aloe; aluminum acetate, carbonate, chlorohydrate and hydroxide; alprozolam; amino acids; aminobenzoic acid; amoxicillin; ampicillin; amsacrine; amsalog; anethole; ascorbic acid; aspartame; astemizole; atenolol; azatidine and its maleate; bacitracin; balsam peru; BCNU (carmustine); beclomethasone diproprionate; benzocaine; benzoic acid; benzophenones; benzoyl peroxide; benzquinamide and its hydrochloride; bethanechol; biotin; bisacodyl; bismuth subsalicylate; born
- Particularly useful active agents are sparingly soluble solid agents whose dissolution and release properties are enhanced by the solubilizing agents used herein.
- These agents include H 2 antagonists, analgesics, including non-steroidal anti- inflammatory drugs (NSAIDs), anticholesterolemics, anti-allergy agents, and anti- migraine agents.
- NSAIDs non-steroidal anti- inflammatory drugs
- anticholesterolemics anti-allergy agents
- anti- migraine agents anti- migraine agents.
- Analgesics include aspirin, acetaminophen, acetaminophen plus caffeine, and non- steroidal anti-inflammatory drugs (NSAIDS), e.g., ibuprofen and nimesulide.
- NSAIDS non- steroidal anti-inflammatory drugs
- Useful NSAIDs include ibuprofen; diclofenac and its alkali metal salts; fenoprofen and its metal salts; flurbiprofen; ketoprofen; naproxen and its alkali metal salts; nimesulide; and piroxicam and its salts.
- H 2 -antagonists which are contemplated for use in the present invention include cimetidine, ranitidine hydrochloride, famotidine, nizatidine, ebrotidine, mifentidine, roxatidine, pisatidine and aceroxatidine.
- Useful anti-allergy agents include hydricodone and its tartrates; clemastine and its fumarate; azatadine and its maleate; acetaminophen; hydroxyzine and its pamoate and hydrochloride salts; chlorpheniramine and its maleates and tannates; pseudoephedrine and its sulfates and hydrochlorides; bromopheniramine and its maleate; dextromethorphan and its hydrohalides; loratadine; phenylephrine and its tannates and hydrochlorides; methscopolamine and its nitrates; phenylpropanolamine and its hydrochlorides; codeine and its hydrochloride; codeine and its phosphate; terfenadine; acrivastine; astemizole; cetrizine and its hydrochloride; phenindamine and its tartrate; tripelennamine and its hydrochloride; cyproh
- Useful antimigraine agents include divalproex and its alkali metal salts; timolol and its maleate; propanolol and its hydrohalides; ergotamine and its tartrate; caffeine; sumatriptan and its succinate; dihydroergotamine, its hydrogenates/mesylates; methsergide and its maleate; isometheptene mucate; and dichloralphenazone.
- antiemetics Another class of drugs which can be used are antiemetics.
- Useful antiemetics include: meclizine and its hydrochloride; hydroxyzine and its hydrochloride and pamoate; diphenhydramine and its hydrochloride; prochlorperazine and its maleate; benzquinamide and its hydrochloride; granisetron and its hydrochloride; dronabinol; bismuth subsalicylate; promethazine and its hydrochloride; metoclopramide and its halides/hydrates; chlorpromazine; trimethobenzamide and its hydrochloride; thiethylperazine and its maleate; scopolamine; perphenazine; and ondansetron and its hydrochloride.
- antidiarrheals such as Imodium AD, antihistamines, antitussives, decongestants, vitamins, and breath fresheners.
- anxiolytics such as Xanax; antipsychotics such as Clozaril and Haldon; antihistamines such as Seldane, Hismanal, Relafen, and Tavist; antiemetics such as Kytril and Cesamet; bronchodilators such as
- statins e.g., lovastatin, provastatin and the like.
- Antacid dosages can be prepared using ingredients such as: aluminum hydroxide, dihydroxyaluminum aminoacetate, aminoacetic acid, aluminum phosphate, dihydroxyaluminum sodium carbonate, bicarbonate, bismuth aluminate, bismuth carbonate, bismuth subcarbonate, bismuth subgallate, bismuth subnitrate, calcium carbonate, calcium phosphate, citrate ion (acid or salt), amino acetic acid, hydrate of magnesium aluminum sulfate, magaldrate, magnesium aluminosilicate, magnesium carbonate, magnesium glycinate, magnesium hydroxide, magnesium oxide, magnesium trisilicate, milk solids, aluminum mono- or di-basic calcium phosphate, tricalcium phosphate, potassium bicarbonate, sodium tartrate, sodium bicarbonate, magnesium aluminosilicates, tartaric acids and salts, and the like. Mixtures are examples of the like.
- Chewable antacid compositions which dissolve quickly can be made using the compositions of the invention.
- Preferred analgesics include aspirin, acetaminophen, acetaminophen plus caffeine, and ibuprofen.
- Other useful active ingredients include antidiarrheals such as IMMODIUM AD; antihistamines; antitussives; decongestants; vitamins and breath fresheners.
- anxiolytics such as XANAX; antipsychotics such as CLOZARIL and HALDOL; non-steroidal antiinflammatories, such as VOLTAREN AND LODINE; antihistamines such as SELDANE, HISMANAL, RELAFEN and TAVIST; antiemetics such as KYTRIL and CESAMET; bronchodilators such as BENTOLIN, PROVENTIL; antidepressants such as PROZAC, ZOLOFT, and PAXIL; antimigraine agents such as IMIGRAN; ace-inhibitors such as VASOTEC, CAPOTEN AND ZESTRIL; anti- Alzheimers agents such as NICERGOLINE; and Ca"-antagonists such as PROCARDIA, ADALAT and CALAN.
- H 2 -antagonists contemplated include cimetidine, ranitidine hydrochloride, famotidine, nizatidine, ebrotidine, mefentidine, roxatidine, pis
- ingredients which may be included are fillers, fragrances, dyes, flavors, sweeteners (both artificial and natural), and other conventional tablet additives.
- fillers may be used to increase the bulk of the tablet.
- Some useful fillers include calcium sulfate, both di- and tri-basic; starch; calcium carbonate; macrocrystalline cellulose; modified starches, lactose, sucrose; mannitol and sorbitol.
- Flavors may be chosen from natural and synthetic flavoring liquids.
- An illustrative list of such agents includes volatile oils, synthetic flavor oils, flavoring aromatics, oils, liquids, oleoresins and extracts derived from plants, leaves, flowers, fruits, stems and combinations thereof.
- a non-limiting representative list of these includes citric - 1 !
- oils such as lemon, orange, grape, lime and grapefruit an fruit essences, including apple, pear, peach, grape, strawberry, raspberry, cherry, plum, pineapple, apricot, or other fruit flavors.
- aldehydes and esters such as benzaldehyde (cherry, almond); citral, i.e., alpha-citral (lemon, lime); neral, i.e., beta-citral (lemon, lime); decanal (orange, lemon); aldehyde C-8 (citrus fruits); aldehyde C-9 (citrus fruits); aldehyde C-12 (citrus fruits); tolyl aldehyde (cherry, almond); 2,6-dimethyloctanal (green fruit); 2-dodedenal (citrus, mandarin); mixtures thereof and the like.
- aldehydes and esters such as benzaldehyde (cherry, almond); citral, i.e., alpha-citral (lemon, lime); neral, i.e., beta-citral (lemon, lime); decanal (orange, lemon); aldehyde C-8 (citrus fruits); al
- the sweeteners may be chosen from the following non-limiting list: glucose (corn syrup), dextrose, invert sugar, fructose, and mixtures thereof (when not used as a carrier); saccharin and its various salts, such as the sodium salt; dipeptide sweeteners such as aspartame; dihydrochalcone compounds, glycyrrhizin; Stevia Rebaudiana (Stevioside); chloro derivatives or sucrose such as sucralose; and sugar alcohols such as sorbitol, mannitol, xylitol, and the like.
- hydrogenated starch hydrolysates and the synthetic sweeteners such as 3 ,6-dihydro-6-methyl- 1-1-1 ,2,3-oxathiazin-4-one- 2,2-dioxide, particularly the potassium salt (acesulfame-K), and sodium and calcium salts thereof.
- Other sweeteners may also be used.
- Some embodiments include one or more effervescent disintegration agents to aid in masking the objectionable taste of active ingredients, such as vitamins, medicines and/or minerals, etc.
- active ingredients such as vitamins, medicines and/or minerals, etc.
- “Effervescent” refers to those agents which evolve gas. The gas- or bubble- generating action is often the result of the reaction of a soluble acid source and a carbonate source. The reaction of these two general classes of compounds produces carbon dioxide gas upon contact with water in saliva.
- Useful acids include: citric, tartaric, malic, fumaric, adipic, succinic and acid salts and anhydrides thereof. Acid salts may also include sodium dihydrogen phosphate, disodium dihydrogen pyrophosphate, acid citrate salts and sodium acid sulfite. While the food acids can be those indicated above, acid anhydrides of the above-described acids may also be used.
- Carbonate sources include dry solid carbonate and bicarbonate salts such as sodium bicarbonate, sodium carbonate, potassium bicarbonate and potassium carbonate, magnesium carbonate and sodium sesquicarbonate, sodium glycine carbonate, L-lysine carbonate, arginine carbonate and amorphous calcium carbonate. Mixtures of various acid and carbonate sources, as well as other sources of effervescence, can be used.
- the effervescent agent can be included in at least three different ways.
- the first method includes incorporating the entire effervescent agent in the feedstock which is used to form the shearform product.
- the second involves adding the agent to an already formed shearform matrix.
- the third method incorporates one portion of the agent in the shearform matrix and adds another portion after formation of the matrix material. The artisan can determine the best way to use the agent for its effervescent properties.
- Binders which contribute to the ease of formation and general quality of the tablet. Binders include starches, pregelatinized starches, gelatin, polyvinylpyrrolidone, methylcellulose, sodium carboxymethylcellulose, ethylcellulose, polyacrylamides, polyvinyloxoazolidone and polyvinylalcohols.
- Color additives can be used in preparing tablets.
- Such color additives include food, drug and cosmetic colors (FD&C), drug and cosmetic colors (D&C) or external drug and cosmetic colors (Ext. D&C).
- FD&C drug and cosmetic colors
- D&C drug and cosmetic colors
- Ext. D&C external drug and cosmetic colors
- These colors are dyes, lakes, and certain natural and derived colorants.
- Useful lakes include dyes absorbed on aluminum hydroxide or other suitable carriers.
- microspheres which are components of substrate/coating systems.
- the substrate can be a non-active ingredient, such as a saccharide-based material, or it can be an active or a combination of actives.
- the substrates are sugar shearlite particles having active agents coated thereon.
- the coating may include other types of coating materials, e.g., coloring agents. Additional coatings can be used.
- substrates which are shearlite particles of one or more actives. Coatings thereon can contain saccharides and other ingredients. Controlled release coatings, e.g., sustained release coatings, are among the preferred types of coatings for use in dosage forms which include bio-affecting agents.
- strong, highly attractive dosage units e.g., tablets, can be produced having textures and internal structures which are relatively open to solubilization.
- compositions are intended generally formed into tablets at pressures of from about 500 up to about 6,000 psi.
- chewable comestible units When chewable comestible units are made, they are typically compressed to hardnesses of about 3 to about 15 SCU's, preferably about 4 to about 6. Tablet thicknesses for chewables are about 0.2 to about 0.3 inches.
- An ibuprofen powder feedstock was fed to the 5 -inch spinning head disclosed in U. S. Patent Application Serial No. 08/874,215 filed on June 13, 1997, entitled A SPINNER HEAD HAVING FLOW RESTRICTING INSERTS.
- the head was rotated at about 3600 rpm while the heating elements were raised to a temperature which produced the liquiflash conditions.
- the feedstock also contained 10% Compritol 888 ATO and 2% Gelucire 50/13.
- Compritol 888 ATO is glycerol behenate NF, a lipophilic additive from Gattefosse S.A., a French company.
- Gelucire a polyethylene glycol 32 glyceryl ester solubility enhancer, is also available from Gattefosse.
- the spinning head forced the material through the screen and the product was permitted to free fall a distance of from 6 to 8 feet below the head.
- the product consists of spheres having a highly consistent particle size, with diameters ranging from about 50 to 200 microns.
- the product was subjected to testing to determine the time required for dissolution of the active ingredient.
- the monograph is provided by the U.S. Pharmacopeial Convention, Inc. In the U.S. Pharmaceopoeial National Formulary Monograph for Ibuprofen Dissolution Study, U.S. 23 NF 18, page 786 (1995). At a composition level of 88% ibuprofen, the time for dissolution of most of the ibuprofen was about 15 minutes. Virtually total dissolution occurred at around 20 to 25 minutes. These results show high predictability for delivery using these microspheres.
- microspheres can be coated with taste masking coatings containing ethyl acrylate and methyl methacrylate polymers and hydroxypropyl methylcellulose polymers.
- Acetaminophen powder (melting point 169-170.5°C) was made into microspheres using a procedure similar to that described in Example I. Fine spheres, all smaller than about 420 microns in diameter, were formed. The spheres were coated with ethyl cellulose polymers and hydroxypropyl cellulose polymers for taste masking.
- EXAMPLE III
- ibuprofen(IBP) microspheres were made from a formulation containing 88% ibuprofen, 10% Compritol and 2% Gelucire.
- a preblend of 78.25% sucrose, 11.0% sorbitol, 10.0% xylitol and 0.75% TWEEN 80 was prepared.
- the Floss preblend was processed using the 5" crown head disclosed in U.S.S.N. 08/854,344, filed May 12, 1997, at a temperature of 250° C and rotational speed of 60Hz (3600rpm).
- the floss collected was chopped in the Littleford FKM600 mixer with 2% lactose (2%w/w of the floss) for 2 minutes at lOOrpm with the choppers on. 200 proof ethanol (0.5% based on weight of the floss) was sprayed on the chopped floss and mixed.
- the floss was then dried at 40-45° C for 60-90 minutes with intermittent mixing.
- the dried floss was screened through a 20 mesh screen.
- microspheres and floss were then admixed used in the following composition:
- the screened floss was blended with ibuprofen microspheres in the Littleford mixer for 5 minutes. To this mix, flavors and flow agent were added and blended for another 2 minutes. Lastly, the lubricant (sodium stearyl fumarate) was added and blended for another 2 minutes. The blend was then tabletted on a Kilian T200 rotary tablet press using 15mm round flat-faced radial edge punches. The tablet weight was maintained at 750mg and the hardness was maintained between 1.0 and 4.0 lb.
- Example IV Reduced Xylitol Floss Using the procedure of Example I, ibuprofen microspheres were made from a formulation containing 88% ibuprofen, 10% Compritol and 2% Gelucire. Via a single floss process similar to that of Example VI, a floss was made from the following composition: 83.25% sucrose, 11.0% sorbitol, 5.0% xylitol and 0.75% TWEEN. The microspheres and floss were used in the following composition:
- EXAMPLE V Acetaminophen Tablets Using a procedure similar to that employed in Example I, acetaminophen (APAP) microspheres were made from a formulation containing 90% APAP, 7.5% carnauba wax, and 2.5% Pluronic F68. The spheres were then coated with a 45:55 mixture of ethyl cellulose and hydroxypropyl cellulose.
- APAP acetaminophen
- composition Percentage 78.25% sucrose, 11.00% sorbitol, 10.00% xylitol and 0.75% Tween 80.
- the floss was chopped in the presence of 2% lactose and granulated after the addition of 0.5% ethanol. Tablets were made from the following composition: Composition Percentage
- Adipic Acid 2.00 Using a Kilian T200 press, 500 mg tablets were pressed to a 2 lb. initial hardness (compaction pressures up to 8000 psi) by placing the composition in the feed hopper and allowing gravity to feed the dies.
- microspheres were made from the following composition:
- Pluronic F68 10 The microspheres were coated for taste masking with a coating containing ethyl cellulose and hydroxypropylcellulose.
- a floss containing 78.25% sucrose, 11.00% sorbitol, 10.0% xylitol and 0.75% Tween 80 was prepared as follows:
- the floss was chopped in a high shear mixer/chopper for 2 minutes.
- the floss was treated with 0.5% ethanol and allowed to dry for 90 minutes.
- the ethanol-treated floss particles were then used in the following formulation:
- the ingredients were mixed in a Littleford Mixer for 10 to 15 minutes.
- the mix was tableted on a Kilian T-200 press to yield 0.65g tablets containing 120mg vitamin C of
- Example VHb Using the floss particles and the general procedure of Example 1, 250mg tablets of ascorbic acid, weighing 1 gram each, were made from the following formulation:
- Examples a and b dissolved in the mouth, without chewing or drinking water, in 5 to 10 seconds.
- the floss was prepared and chopped using the general procedure of Example VII.
- the chopped floss was treated with 4.0% ethanol and allowed to dry for 90 minutes.
- the 4.0% ethanol- treated floss particles were then used in the following formulation.
- the ingredients were mixed in a Littleford Mixer for 10 to 20 minutes.
- the mix was tableted on a Kilian T-200 press to yield 1.75g tablets of 11 pounds hardness, having a thickness of 6.5 to 7.5mm.
- sucrose, sorbitol, xylitol, and Polysorbate 80 were blended in a Littleford
- the floss manufactured was chopped in the Littleford FKM600 mixer with 2% lactose and treated with ethanol (7% of the floss). The floss was dried at 45°C for 150 minutes. The floss was then milled/sieved through a 20 mesh screen using a Fitzmill or Apexmill.
- the calcium carbonate was blended with Vitamin D 3 for 15 minutes at speed 1 in a Diosna 600.
- the milled floss was added and blended further for 10 minutes.
- the flavors and flow agent was added and blended for additional 3 minutes.
- the magnesium stearate was added and blended for additional 7 minutes.
- the blend was compressed on a rotary tablet press at 85N hardness, 2.75g tablet weight, 19mm concave round or 19mm flat-faced radial edge tooling.
- Example X The calcium carbonate was blended with floss for 10 minutes in a Littleford FKM 600 mixer. The flavor and mannitol was added and blended further for 3 minutes. The flow agent was added and blended for additional 3 minutes. The magnesium stearate was added and blended for an additional 4 minutes. The blend was compressed on a Kilian rotary tablet press to 100-120 N hardness, 1.5g tablet weight, using 16.5mm flat faced radial edge tooling.
- Example X Example X
- Chewable ibuprofen tablets were made from the following formulations:
- Polysorbate 80 0.5 The floss preblend was processed using the 5" crown head disclosed in U.S.S.N.
- the floss collected was chopped in the Stephan mixer for 1-2 minutes at "hi" speed setting.
- 200 proof ethanol (4% of the formulation) was sprayed on the chopped floss with simultaneous mixing in a Hobart planetary mixer.
- the floss was then placed in flat trays and dried at 35-40°C for 60-90 minutes with intermittent agitation in an oven.
- the dried floss was screened through a 20 mesh screen using a Quadro Comil.
- the dry granulation was mixed with tablet excipients, as follows:
- the floss preblend was processed using the 5" crown head disclosed in U.S.S.N.
- the floss collected was chopped in the Stephan mixer for 1-2 minutes at "hi" speed setting. 200 proof ethanol (4% of the formulation) was sprayed on the chopped floss with simultaneous mixing in a Hobart planetary mixer. The floss was then placed in flat trays and dried at 35-40° C for 60-90 minutes with intermittent agitation. The floss was screened through a 20 mesh screen using a Quadro comil. The screened floss was blended with ibuprofen microspheres in the Hobart planetary mixer for 3-5 minutes. Flavors and flow agents were added and blended for another 2-4 minutes. Lastly, the lubricant (magnesium stearate) was added and blended for an additional 2 minutes.
- lubricant magnesium stearate
- the blend was then tabletted on a Stokes rotary tablet press using round flat-faced beveled edge tooling to give tablets having varying weights, as follows:
- the punch size was 5/8" for 200mg ibuprofen equivalent tablets (1.2g tablets), 1/2" for lOOmg ibuprofen equivalent tablets (0.6g tablets), and 3/8" for 50mg ibuprofen equivalent tablets (0.3g tablets).
- the hardness of the tablets was maintained between 3.0 and 7.0 SCU.
- the following table shows quantity ranges in which various ingredients can be used to make chewable ibuprofen tablets via procedures such as those described above.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98938459A EP1001746A1 (en) | 1997-08-20 | 1998-08-11 | Fast-dissolving comestible units formed under high-speed/high-pressure conditions |
AU86983/98A AU8698398A (en) | 1997-08-20 | 1998-08-11 | Fast-dissolving comestible units formed under high-speed/high-pressure conditions |
JP2000509398A JP2001515028A (en) | 1997-08-20 | 1998-08-11 | A rapidly dissolving oral dosage unit formed under high speed / high pressure conditions |
CA002301228A CA2301228A1 (en) | 1997-08-20 | 1998-08-11 | Fast-dissolving comestible units formed under high-speed/high-pressure conditions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/915,067 | 1997-08-20 | ||
US08/915,067 US5869098A (en) | 1997-08-20 | 1997-08-20 | Fast-dissolving comestible units formed under high-speed/high-pressure conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999008658A1 true WO1999008658A1 (en) | 1999-02-25 |
Family
ID=25435157
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/016520 WO1999008658A1 (en) | 1997-08-20 | 1998-08-11 | Fast-dissolving comestible units formed under high-speed/high-pressure conditions |
Country Status (6)
Country | Link |
---|---|
US (2) | US5869098A (en) |
EP (1) | EP1001746A1 (en) |
JP (1) | JP2001515028A (en) |
AU (1) | AU8698398A (en) |
CA (1) | CA2301228A1 (en) |
WO (1) | WO1999008658A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000009171A1 (en) * | 1998-08-12 | 2000-02-24 | Fuisz Technologies Ltd. | Products containing unpleasant tasting bio-affecting agents and methods of making them |
WO2000009639A2 (en) * | 1998-08-12 | 2000-02-24 | Fuisz Technologies Ltd. | Fatty ester combinations |
WO2000023040A1 (en) * | 1998-10-16 | 2000-04-27 | Fuisz Technologies Ltd. | Dry deodorizing composition for oral administration |
WO2000025755A1 (en) * | 1998-10-30 | 2000-05-11 | Fuisz Technologies Ltd. | Dosage forms containing taste masked active agents |
US9101625B2 (en) | 2006-08-30 | 2015-08-11 | Purdue Pharma L.P. | Buprenorphine-wafer for drug substitution therapy |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5980941A (en) * | 1997-08-20 | 1999-11-09 | Fuisz Technologies Ltd. | Self-binding shearform compositions |
US6277406B1 (en) | 1997-10-08 | 2001-08-21 | Fuisz Technologies Ltd. | Easily processed tablet compositions |
JP2002505269A (en) * | 1998-03-06 | 2002-02-19 | エウランド インターナショナル ソシエタ ペル アチオニ | Rapidly disintegrating tablets |
US8524277B2 (en) * | 1998-03-06 | 2013-09-03 | Alza Corporation | Extended release dosage form |
US6270804B1 (en) * | 1998-04-03 | 2001-08-07 | Biovail Technologies Ltd. | Sachet formulations |
KR101032289B1 (en) * | 1998-05-18 | 2011-05-06 | 다케다 야쿠힌 고교 가부시키가이샤 | Fine granules |
US20040013613A1 (en) * | 2001-05-18 | 2004-01-22 | Jain Rajeev A | Rapidly disintegrating solid oral dosage form |
US8236352B2 (en) * | 1998-10-01 | 2012-08-07 | Alkermes Pharma Ireland Limited | Glipizide compositions |
US7815937B2 (en) * | 1998-10-27 | 2010-10-19 | Biovail Laboratories International Srl | Quick dissolve compositions and tablets based thereon |
FR2785538B1 (en) * | 1998-11-06 | 2004-04-09 | Prographarm Laboratoires | PERFECTED QUICK DELIVERY TABLET |
US20030026835A1 (en) * | 1999-02-15 | 2003-02-06 | Sumitomo Pharmaceuticals Company Limited | Tablets disintegrating rapidly in the oral cavity |
US6248760B1 (en) * | 1999-04-14 | 2001-06-19 | Paul C Wilhelmsen | Tablet giving rapid release of nicotine for transmucosal administration |
GB9910505D0 (en) | 1999-05-06 | 1999-07-07 | Electrosols Ltd | A method and apparatus for manufacturing consumable tablets |
US20040115134A1 (en) * | 1999-06-22 | 2004-06-17 | Elan Pharma International Ltd. | Novel nifedipine compositions |
CA2382978A1 (en) * | 1999-10-20 | 2001-04-26 | Wm. Wrigley Jr. Company | Powder pharmaceutical formulations |
WO2001039749A2 (en) * | 1999-11-30 | 2001-06-07 | Panacea Biotec Limited | Fast dissolving composition with prolonged sweet taste |
WO2001054667A1 (en) * | 2000-01-28 | 2001-08-02 | Smithkline Beecham Corporation | Electrospun pharmaceutical compositions |
WO2001064224A1 (en) * | 2000-02-29 | 2001-09-07 | Teva Pharmaceutical Industries Ltd. | Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same |
US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
US20030109577A1 (en) * | 2000-10-27 | 2003-06-12 | Ken Liljegren | Pharmaceutical composition containing citalopram |
AU2002220248A1 (en) * | 2000-11-06 | 2002-05-15 | Andrx Pharmaceuticals, Inc. | Once a day antihistamine and decongestant formulation |
US6982251B2 (en) * | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
PT1413331E (en) * | 2001-01-26 | 2007-12-18 | Schering Corp | Combinations of the peroxisome proliferator-activated receptor (ppar) activator fenofibrate with sterol absorption inhibitor ezetimibe for vascular indications |
US20060287254A1 (en) * | 2001-01-26 | 2006-12-21 | Schering Corporation | Use of substituted azetidinone compounds for the treatment of sitosterolemia |
MXPA03007081A (en) * | 2001-02-08 | 2004-10-15 | Pharmacia Corp | Rapid-onset medicament for the treatment of sexual dysfunction. |
BR0207930A (en) | 2001-03-05 | 2004-03-02 | Ortho Mcneil Pharm Inc | Masked flavor liquid pharmaceutical compositions |
WO2002076425A2 (en) * | 2001-03-22 | 2002-10-03 | Battelle (Memorial Institute) | Manufacturing dissolvable dosage forms |
FR2822643B1 (en) * | 2001-03-30 | 2005-03-04 | Roquette Freres | PROCESS FOR PREPARING A HYPOCALORIC FOOD |
US20020198228A1 (en) * | 2001-04-03 | 2002-12-26 | Kaura Sita R. | Composition and method for the treatment of respiratory desease |
WO2002087544A1 (en) * | 2001-04-17 | 2002-11-07 | Wm. Wrigley Jr. Company | Flavored product containing medicament or other active agent |
ATE352546T1 (en) | 2001-07-31 | 2007-02-15 | Lundbeck & Co As H | CRYSTALLINE COMPOSITION CONTAINING ESCITALOPRAM |
BR0212259A (en) * | 2001-08-29 | 2004-10-19 | Ranbaxy Lab Ltd | Controlled release formulation of clarithromycin or tinidazole |
US7053080B2 (en) * | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
ATE345793T1 (en) * | 2001-09-21 | 2006-12-15 | Schering Corp | TREATMENT OF XANTHOMA USING AZETIDINONE DERIVATIVES AS STEROL ABSORPTION INHIBITORS |
US6908626B2 (en) * | 2001-10-12 | 2005-06-21 | Elan Pharma International Ltd. | Compositions having a combination of immediate release and controlled release characteristics |
MY148466A (en) * | 2001-10-26 | 2013-04-30 | Merck Frosst Canada Ltd | Granule formulation |
US6887926B1 (en) | 2001-11-16 | 2005-05-03 | Oatey Co. | Bonding compositions for chlorinated polymers and methods of using the same |
EP1941878A1 (en) | 2002-01-10 | 2008-07-09 | Biovail Laboratories International Srl | Sedative non-benzodiazepine formulations |
DE10207394B4 (en) * | 2002-02-21 | 2007-03-29 | Lts Lohmann Therapie-Systeme Ag | Taste-masked oblate medicinal preparation |
CA2479735C (en) * | 2002-03-20 | 2011-05-17 | Elan Pharma International Ltd. | Fast dissolving dosage forms having reduced friability |
US20040001885A1 (en) * | 2002-06-27 | 2004-01-01 | Unchalee Kositprapa | Rapidly disintegrating antihistamine formulation |
US20030017208A1 (en) * | 2002-07-19 | 2003-01-23 | Francis Ignatious | Electrospun pharmaceutical compositions |
WO2004032853A2 (en) * | 2002-10-04 | 2004-04-22 | Pharmacia Corporation | Compositions and methods for treating sexual dysfunction |
US8092831B2 (en) * | 2002-11-08 | 2012-01-10 | Andrx Pharmaceuticals, Llc | Antihistamine and decongestant system |
JP4776233B2 (en) * | 2002-11-12 | 2011-09-21 | エラン ファーマ インターナショナル,リミティド | Fast disintegrating solid formulation that is resistant to abrasion and contains pullulan |
US20040156894A1 (en) * | 2003-02-07 | 2004-08-12 | Grother Leon Paul | Use of edible acids in fast-dispersing pharmaceutical solid dosage forms |
US20040162333A1 (en) * | 2003-02-19 | 2004-08-19 | Naima Mezaache | Rapid absorption selective 5-HT agonist formulations |
US7459442B2 (en) * | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
US7235543B2 (en) | 2003-03-07 | 2007-06-26 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
EP1606287B1 (en) * | 2003-03-07 | 2013-10-02 | Merck Sharp & Dohme Corp. | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
US7208486B2 (en) * | 2003-03-07 | 2007-04-24 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
CA2524806C (en) * | 2003-05-07 | 2011-07-12 | Akina, Inc. | Highly plastic granules for making fast melting tablets |
US20050036977A1 (en) * | 2003-08-11 | 2005-02-17 | Dilip Gole | Taste-masked resinate and preparation thereof |
WO2005034921A1 (en) * | 2003-10-07 | 2005-04-21 | Andrx Pharmaceuticals Llc | Rapidly disintegrating formulation |
WO2005053652A1 (en) | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride |
US6984403B2 (en) * | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
BRPI0416535A (en) * | 2003-12-04 | 2007-01-09 | Pfizer Prod Inc | spray freezing process employing an extruder to prepare multiparticulate azithromycin compositions preferably containing a poloxamer and a glyceride |
WO2005053639A2 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Controlled release multiparticulates formed with dissolution enhancers |
WO2005053651A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate compositions with improved stability |
RU2006119453A (en) * | 2003-12-04 | 2007-12-20 | Пфайзер Продактс Инк. (Us) | PRODUCTION OF MEDICINES ASITROMYCIN WITH A LARGE NUMBER OF PARTICLES BASED ON THE APPLICATION OF LIQUIDS OF METHODS |
ES2600577T3 (en) * | 2003-12-04 | 2017-02-09 | Bend Research, Inc. | Spray-solidification process using an extruder to prepare multiparticulate compositions of crystalline drugs |
ATE399536T1 (en) * | 2003-12-04 | 2008-07-15 | Pfizer Prod Inc | METHOD FOR PRODUCING PHARMACEUTICAL MULTIPARTICLE PRODUCTS |
US20050163867A1 (en) * | 2004-01-23 | 2005-07-28 | James Schachtel | Composition and method of treating gastric ulcers in mammals |
ITMI20042356A1 (en) * | 2004-12-10 | 2005-03-10 | Acraf | ORODISPERSIBLE PHARMACEUTICAL COMPOSITION AND PROCEDURE FOR PREPARING IT |
US20070020186A1 (en) * | 2005-07-22 | 2007-01-25 | Alpex Pharma S.A. | Solid dosage formulations of narcotic drugs having improved buccal adsorption |
EP1909910A1 (en) | 2005-08-04 | 2008-04-16 | Sirtris Pharmaceuticals, Inc. | Benzimidazole derivatives as sirtuin modulators |
US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US7811604B1 (en) | 2005-11-14 | 2010-10-12 | Barr Laboratories, Inc. | Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same |
WO2007091856A1 (en) * | 2006-02-10 | 2007-08-16 | Lg Household & Health Care Ltd. | In-situ melting and gelling tablet composition for oral care |
US20070243248A1 (en) * | 2006-04-14 | 2007-10-18 | Cherukuri S Rao | Rapidly disintegrating solid oral dosage form of liquid dispersions |
CN101431895A (en) * | 2006-05-01 | 2009-05-13 | 卡普里康制药公司 | Novel triptan formulations and methods for making them |
EP2043613A1 (en) * | 2006-07-14 | 2009-04-08 | Fmc Corporation | Solid form |
US20080187628A1 (en) * | 2007-02-02 | 2008-08-07 | Champion Melinda L | Water-Soluble, Quick-Dissolve Flavor Tablets |
US20080311162A1 (en) * | 2007-05-16 | 2008-12-18 | Olivia Darmuzey | Solid form |
AU2009219292B2 (en) * | 2008-02-28 | 2014-02-27 | R.P. Scherer Technologies, Llc | Process to minimize polymorphism |
WO2009120382A1 (en) | 2008-03-27 | 2009-10-01 | Zpower, Inc. | Electrode separator |
US20110097401A1 (en) * | 2009-06-12 | 2011-04-28 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
US8397945B2 (en) | 2010-02-23 | 2013-03-19 | R.J. Reynolds Tobacco Company | Dispensing container |
EP2544665A4 (en) * | 2010-03-11 | 2014-01-01 | Rich Vitamins Llc | Quick dissolve nutritional powder |
SG10201506873WA (en) | 2010-09-01 | 2015-10-29 | Arena Pharm Inc | Fast-dissolve dosage forms of 5-ht2c agonists |
US9474303B2 (en) | 2011-09-22 | 2016-10-25 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
US9629392B2 (en) | 2011-09-22 | 2017-04-25 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
US20130078307A1 (en) | 2011-09-22 | 2013-03-28 | Niconovum Usa, Inc. | Nicotine-containing pharmaceutical composition |
US9084439B2 (en) | 2011-09-22 | 2015-07-21 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
MX345902B (en) * | 2011-12-08 | 2017-02-23 | Hershey Co | Rapidly dissolving comestible solid. |
US9763928B2 (en) | 2012-02-10 | 2017-09-19 | Niconovum Usa, Inc. | Multi-layer nicotine-containing pharmaceutical composition |
US9044035B2 (en) | 2012-04-17 | 2015-06-02 | R.J. Reynolds Tobacco Company | Remelted ingestible products |
EP3524247A1 (en) | 2013-11-11 | 2019-08-14 | Impax Laboratories, Inc. | Rapidly disintegrating formulations and methods of use |
US11324699B2 (en) | 2014-12-04 | 2022-05-10 | Capsugel Belgium Nv | Lipid multiparticulate formulations |
JP6907118B2 (en) * | 2015-01-14 | 2021-07-21 | ピーエフ、コンシューマー、ヘルスケア、1、リミテッド、ライアビリティー、カンパニーPF Consumer Healthcare 1 LLC | Oral delivery product |
US9925138B2 (en) | 2015-01-20 | 2018-03-27 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
EP3288556A4 (en) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
DE202015004009U1 (en) | 2015-06-09 | 2016-01-11 | Hermes Arzneimittel Gmbh | Fast disintegrating tablets without decay accelerator |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
DE202016005032U1 (en) | 2016-08-19 | 2017-02-10 | Hermes Arzneimittel Gmbh | Fast disintegrating Ivy drinking tablets without decay accelerator |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0711547A1 (en) * | 1994-11-04 | 1996-05-15 | Fuisz Technologies Ltd. | Delivery of controlled-release system(s) with shearform matrix |
US5587172A (en) * | 1993-09-10 | 1996-12-24 | Fuisz Technologies Ltd. | Process for forming quickly dispersing comestible unit and product therefrom |
US5601076A (en) * | 1993-09-10 | 1997-02-11 | Fuisz Technologies Ltd. | Spheroidal crystal sugar and method of making |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5686094A (en) * | 1991-04-01 | 1997-11-11 | Theratech, Inc. | Controlled release formulations for the treatment of xerostomia |
CA2128820A1 (en) * | 1993-07-27 | 1995-01-28 | Walter G. Gowan, Jr. | Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof |
US5646131A (en) * | 1994-02-22 | 1997-07-08 | The Arab Company For Drug Industries And Medical Applicances (Acdima) | Method for solubilizing drugs using cyclodextrins and carboxylic acids |
US5683720A (en) * | 1994-10-28 | 1997-11-04 | Fuisz Technologies Ltd. | Liquiflash particles and method of making same |
-
1997
- 1997-08-20 US US08/915,067 patent/US5869098A/en not_active Expired - Lifetime
-
1998
- 1998-08-11 AU AU86983/98A patent/AU8698398A/en not_active Abandoned
- 1998-08-11 EP EP98938459A patent/EP1001746A1/en not_active Withdrawn
- 1998-08-11 JP JP2000509398A patent/JP2001515028A/en active Pending
- 1998-08-11 WO PCT/US1998/016520 patent/WO1999008658A1/en not_active Application Discontinuation
- 1998-08-11 CA CA002301228A patent/CA2301228A1/en not_active Abandoned
- 1998-08-12 US US09/132,986 patent/US6048541A/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5587172A (en) * | 1993-09-10 | 1996-12-24 | Fuisz Technologies Ltd. | Process for forming quickly dispersing comestible unit and product therefrom |
US5601076A (en) * | 1993-09-10 | 1997-02-11 | Fuisz Technologies Ltd. | Spheroidal crystal sugar and method of making |
EP0711547A1 (en) * | 1994-11-04 | 1996-05-15 | Fuisz Technologies Ltd. | Delivery of controlled-release system(s) with shearform matrix |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000009171A1 (en) * | 1998-08-12 | 2000-02-24 | Fuisz Technologies Ltd. | Products containing unpleasant tasting bio-affecting agents and methods of making them |
WO2000009639A2 (en) * | 1998-08-12 | 2000-02-24 | Fuisz Technologies Ltd. | Fatty ester combinations |
WO2000009639A3 (en) * | 1998-08-12 | 2002-09-19 | Fuisz Technologies Ltd | Fatty ester combinations |
WO2000023040A1 (en) * | 1998-10-16 | 2000-04-27 | Fuisz Technologies Ltd. | Dry deodorizing composition for oral administration |
WO2000025755A1 (en) * | 1998-10-30 | 2000-05-11 | Fuisz Technologies Ltd. | Dosage forms containing taste masked active agents |
US9101625B2 (en) | 2006-08-30 | 2015-08-11 | Purdue Pharma L.P. | Buprenorphine-wafer for drug substitution therapy |
US9370512B2 (en) | 2006-08-30 | 2016-06-21 | Purdue Pharma L.P. | Buprenorphine-wafer for drug substitution therapy |
US9763931B2 (en) | 2006-08-30 | 2017-09-19 | Purdue Pharma L.P. | Buprenorphine-wafer for drug substitution therapy |
US9861628B2 (en) | 2006-08-30 | 2018-01-09 | Rhodes Pharmaceuticals L.P. | Buprenorphine-wafer for drug substitution therapy |
Also Published As
Publication number | Publication date |
---|---|
US5869098A (en) | 1999-02-09 |
JP2001515028A (en) | 2001-09-18 |
EP1001746A1 (en) | 2000-05-24 |
AU8698398A (en) | 1999-03-08 |
US6048541A (en) | 2000-04-11 |
CA2301228A1 (en) | 1999-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6048541A (en) | Fast-dissolving comestible units formed under high-speed/high-pressure conditions | |
US6165512A (en) | Dosage forms containing taste masked active agents | |
US5840334A (en) | Self-binding shearform compositions | |
US5980941A (en) | Self-binding shearform compositions | |
US6270804B1 (en) | Sachet formulations | |
US7815937B2 (en) | Quick dissolve compositions and tablets based thereon | |
US5567439A (en) | Delivery of controlled-release systems(s) | |
US20120082729A1 (en) | Quick dissolve compositions and tablets based thereon | |
US7914811B2 (en) | Brittle-coating, soft core dosage form | |
WO1999008659A1 (en) | Process for improving flow and compression of tableting compositions | |
WO1999008655A1 (en) | Quick disintegrating tablets | |
IE980519A1 (en) | Quick disintegrating tablets |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2301228 Country of ref document: CA Ref country code: CA Ref document number: 2301228 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998938459 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1998938459 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998938459 Country of ref document: EP |